Molecular Templates, Inc. MTEM
Set alert
0.00 USD 0.00 0.00%
As of Aug 13, 9:30 AM ET
0.0001 Day range 0.0001
52-week range unavailable
- YTD
- -99.91%
- 1 year
- -99.91%
- Open
- 0.0001
- Prev close
- 0.0001
- Mkt cap
- 921.74K
- Vol
- 5
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0001
- Forward P/E
- -0.06
- Beta
- 1.22
- Short ratio
- 0.01
- Inst. own
- 35.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 23, 2024
- 50-d avg
- 0.4644
- 200-d avg
- 1.27
- 1y target
- 0.00
2Y chart
Events in this range
- Aug 10, 2023Earnings: -3.3; estimate -5.25; surprise 37.14%
- Aug 14, 2023Split: 1 for 15
- Nov 13, 2023Earnings: -0.82; estimate -2.7; surprise 69.63%
- May 15, 2024Earnings: 0.08; estimate 0; surprise —%
- Aug 14, 2024Earnings: -1.23; estimate 0; surprise —%
- Dec 23, 2024Earnings: —; estimate 0; surprise —%
Signals (53)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| RSI: Oversold | Mar 14, 2025 | 1 year ago |
| RSI: Oversold | Jan 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 13, 2025 | 1 year ago |
| RSI: Oversold | Dec 23, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 20, 2024 | 1 year ago |
| RSI: Oversold | Nov 8, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 7, 2024 | 1 year ago |
| SMA: Bearish | Oct 14, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 14, 2024 | 2 years ago |
| RSI: Oversold | Oct 14, 2024 | 2 years ago |
| SMA: Bearish | Oct 1, 2024 | 2 years ago |
| SMA: Bullish | Sep 27, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 25, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 23, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 20, 2024 | 2 years ago |
| RSI: Oversold | Sep 9, 2024 | 2 years ago |
| SMA: Bearish | Sep 6, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 28, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 15, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 14, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 13, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 6, 2024 | 2 years ago |
| SMA: Bullish | Jul 10, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 28, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 24, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 3, 2024 | 2 years ago |
| MACD: Sell Signal | May 24, 2024 | 2 years ago |
| RSI: Oversold | May 24, 2024 | 2 years ago |
| RSI: Oversold | Apr 17, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 5, 2024 | 2 years ago |
| RSI: Oversold | Apr 3, 2024 | 2 years ago |
| RSI: Oversold | Mar 12, 2024 | 2 years ago |
| SMA: Bearish | Mar 6, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 5, 2024 | 2 years ago |
| SMA: Bullish | Mar 4, 2024 | 2 years ago |
| SMA: Bearish | Mar 1, 2024 | 2 years ago |
| SMA: Bullish | Feb 20, 2024 | 2 years ago |
| RSI: Oversold | Jan 3, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 28, 2023 | 2 years ago |
| RSI: Oversold | Dec 21, 2023 | 2 years ago |
| RSI: Oversold | Dec 13, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 12, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 24, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 21, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 10, 2023 | 2 years ago |
| RSI: Oversold | Nov 1, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 30, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 20, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 19, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 4, 2023 | 3 years ago |
| RSI: Oversold | Sep 28, 2023 | 3 years ago |
| RSI: Oversold | Sep 15, 2023 | 3 years ago |
Key statistics
- Market cap
- 921.74K
- Enterprise value
- 2.42M
- Trailing P/E
- 0.00
- Forward P/E
- -0.06
- PEG ratio
- 0.00
- Price / sales
- 0.04
- Price / book
- 0.13
- EPS (TTM)
- -3.05
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -61.35%
- Revenue (TTM)
- 25.47M
- Revenue growth
- -91.70%
- Free cash flow
- -17.50M
- Total cash
- 9.66M
- Total debt
- 11.03M
- Return on equity
- 0.00%
- Shares outstanding
- 6.58M
- Short % of float
- 4.57%
- 50-day average
- 0.4644
- 200-day average
- 1.27
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Dec 23, 2024
Expected Dec 23, 2024. Consensus EPS estimate 0.00.
Financials — quick view
MTEM Revenue — quarterly 572.00K
MTEM Net income — quarterly -8.10M
MTEM EPS — quarterly -1.23
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 23, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -1.23 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | 0.08 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -2.10 | -0.73 | +1.37 | +65.24% |
| Nov 13, 2023 | Sep 1, 2023 | -2.70 | -0.82 | +1.88 | +69.63% |
| Aug 10, 2023 | Jun 1, 2023 | -5.25 | -3.30 | +1.95 | +37.14% |
About Molecular Templates, Inc.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mtem.com
News
- RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
- Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
- Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket
- Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
Your note
Sign in to keep a note on MTEM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIOTECH TARGET N V | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 13, 2024 | 0 |
| LALANDE KEVIN M | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Apr 1, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bellevue Group AG | 19.44% | 1,279,820 | 179.17K | Sep 29, 2024 |
| SilverArc Capital Management, LLC | 9.48% | 623,838 | 87.34K | Sep 29, 2024 |
| BVF Inc. | 7.93% | 522,238 | 73.11K | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 1.11% | 73,125 | 10.24K | Sep 29, 2024 |
| Vanguard Group Inc | 0.77% | 50,899 | 7.13K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.72% | 47,231 | 6.61K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.76% | 49,888 | 6.98K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 29,300 | 4.10K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 7,016 | 982 | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 3,964 | 554 | Oct 30, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 14 | 1 | Aug 30, 2024 |